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bo the Editor: Acute renal injury after exposure to radiographic
ontrast media, contrast-induced nephropathy (CIN), accounts for
substantial proportion of all cases of acute renal failure (1). The
ncremental presence of predisposing factors including pre-existing
hronic renal impairment, contrast load, diabetes, and advancing
ge contribute significantly to the risk of CIN, which may exceed
0% in the highest-risk patients (2). Due to common risk factors,
atients undergoing coronary angiography or coronary interven-
ion represent a particularly high-risk group. The development of
IN is a major source of clinical concern for several reasons. First,
ontrast-induced renal injury may in some cases contribute to a
ermanent worsening of renal function, in some cases requiring
emporary or even permanent dialysis. Second, in patients under-
Figure 1 CS Aspiration System and Renoprotective Effect
Schematic (A) and fluoroscopic image (B) of the contrast removal system and cathet
strating changes in the estimated glomerular filtration rate (eGFR) from baseline (solidoing coronary intervention, it is increasingly evident that the
evelopment of CIN is accompanied by higher periprocedural
ortality, longer hospitalization, and a higher likelihood of com-
lications (3).
Given the incidence of CIN and its clinical implications, there has
een considerable interest in the development of strategies to reduce
he risk of CIN. These include periprocedural hydration with saline or
odium bicarbonate, and treatment with N-acetylcysteine, although
heir effectiveness is controversial. Given the strong relationship
etween the volume of contrast media and CIN incidence, an
lternate strategy is to limit the systemic contrast exposure. We
herefore evaluated the possibility that renal contrast exposure could
e limited by removing contrast-laden blood from the coronary sinus
support device (arrow) deployed in the coronary sinus (CS). (C) Bar graph demon-
to follow-up (open bars) in control and CS aspiration groups. Std  standard.er with
bars)
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August 3, 2010:525–30CS) during and immediately after the intracoronary injection of
ontrast media.
We report here the initial experience with a system developed
or the aspiration of contrast media from the CS during coronary
ngiography and intervention (CINCOR Contrast Removal System,
sprey Medical, St. Paul, Minnesota). The primary aim of the study
as to evaluate the safety and efficacy of this approach, and second-
rily we examined its ability to limit the decline in renal function after
ontrast exposure. A purpose-designed 11-F CS aspiration catheter
nd CS support device were placed via a 14-F right internal jugular
ein sheath. The CS was successfully cannulated with the aspiration
atheter in 31 of 41 patients. The mean time to cannulate the CS was
1.1  9.3 min. There were no device-related serious adverse events.
ur cohort included 26 patients with an estimated glomerular
ltration rate (eGFR) of 60 ml/min that were evaluated for renal
utcomes (5 pilot-phase patients had normal renal function). In this
roup, there was no change in eGFR from baseline to 72 h
ost-procedure (41.8 2.2 ml/min to 41.1 2.3 ml/min, p 0.55)
Fig. 1). By comparison, a matched comparator cohort of 148
tandard care patients (4) receiving a similar contrast load experi-
nced a significant decrease in the eGFR from 42.7  0.8 ml/min
o 40.1  0.9 ml/min (p  0.001) at 48 h. There was a greater net
ecrease in the eGFR in the comparator group: 2.5  0.5
l/min versus0.7 1.2 ml/min, p 0.05. The average amount
f blood collected by CS aspiration was 169 15 ml per patient, and
his resulted in a clinically small but statistically significant decrease in
emoglobin from 12.3  0.2 g/dl to 11.7  0.2 g/dl (p  0.01).
n 65 standard care patients with a baseline eGFR 40 ml/min,
he eGFR fell from 33.1 0.7 ml/min to 31.7 0.8 ml/min (p
.003), whereas in those with concomitant CS aspiration and an
GFR 40 ml/min (n  11), there was no change in the eGFR
30.7  1.6 ml/min to 31.4  1.8 ml/min, p  0.42). The
etween-group difference in the eGFR response was 1.5  0.5
l/min versus0.5 0.7 ml/min (p 0.05). In patients undergoing
S aspiration, we quantified the extent of radiographic contrast
apture. Unlike other experimental studies of CS capture, we directly
easured the concentration of iodine in the collected material using
nductively coupled plasma-optical emission spectroscopy. CS con-
rast aspiration resulted in the recapture of 32  3% of the
elivered contrast, ranging from 6% to 64%.
Taken together, the present study provides supportive evidence of
he safety and feasibility of a CS-based aspiration system for the
emoval of radiographic contrast in patients undergoing coronary
ngiography and intervention. Our data also provide a preliminary
ndication that the collection of contrast from the CS reduces systemic
xposure and, in conjunction, attenuates expected nephrotoxicity.
hese data warrant further evaluation in a large-scale randomized trial
o evaluate the capacity of CS contrast capture to reduce the risk of
ontrast-induced nephropathy and its complications.
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Letters to the Editor
istinct Patterns of
utoantibodies Against
-Protein–Coupled Receptors
n Chagas’ Cardiomyopathy
nd Megacolon
heir Potential Impact
or Early Risk Assessment
n Asymptomatic Chagas’ Patients
e demonstrated in the Journal (1) that patients with Chagas’
isease suffering from cardiomyopathy and megacolon show pos-
tivity of autoantibodies directed to the beta1-adrenoreceptor
AAB), beta2-AAB, and muscarinergic2-receptor (M2-AAB). A
ubset of nearly 35% of asymptomatic Chagas’ patients also
resented with AAB patterns indicative of either cardiomyopathy
beta1-AAB and M2-AAB) or megacolon (beta2-AAB and M2-
AB). Because the numbers of AAB positive but asymptomatic
ubjects paralleled the epidemiological data for the percentage of
